Improving Diagnosis and Treatment of Appendiceal Cancers

close up of cells

Appendiceal cancers are rare, with an estimated 1,500 people diagnosed per year in the United States. The rarity of these cancers and their diverse manifestations can make accurate diagnosis challenging.

Read More

Higher Mortality and Hospital Use Linked to Dependency in Instrumental Activities of Daily Living Among Cancer Patients

Elderly couple cooking together

A recent study out of Brigham and Women’s Hospital advises that older cancer patients receive routine assessments of their ability to conduct certain daily living activities to identify those who need supportive intervention. The study, led by Clark DuMontier, MD, geriatrician and research fellow in Brigham and Women’s Division of Aging, found a correlation between patients’ ability to live independently and their odds of being hospitalized or dying.

Read More

Exploring a New Combination Therapy to Prevent Renal Cell Cancer Recurrence

close-up of cells

Immune checkpoint inhibitors have transformed the management of patients with advanced kidney cancer. However, these therapies only work for a subset of patients with advanced disease and can be associated with substantial side effects. As a result, researchers are focused on new therapeutic combinations to boost the effectiveness of current immune therapies in renal cancer, including in patient populations with early-stage disease that is likely to recur.

Read More

Patients Taking PARP Inhibitor Survive Ovarian Cancer Longer with Fewer Complications

dna strand

Ovarian cancer is one of the deadliest forms of women’s cancer, with a five-year survival rate of 47.4 percent. The standard of care for first-line treatment is platinum- and taxane-based chemotherapy, which results in high initial response rates.

Read More

Acute Kidney Injury Associated With Immune Checkpoint Inhibitors

acute kidney injury

Researchers at Brigham and Women’s Hospital have identified several links between the use of immune checkpoint inhibitors (ICPIs) and acute kidney injury (AKI). The risk factors, clinicopathologic features, treatment and long-term outcomes in patients with ICPI-associated AKI, as well as the risk of recurrent AKI with ICPI rechallenge, are detailed in a multicenter study recently published in the Journal of the American Society of Nephrology. These newly identified links will help guide oncologists in treating patients with ICPIs.

Read More

Metabolic Imbalances Linked to Cancer Therapy Resistance

series of test tubes

Immune checkpoint inhibitors (ICIs), or blockers, have revolutionized the way some cancer patients are treated. However, effects of these treatments can vary from patient to patient. In some cases, cancer cells and/or the tumor microenvironment can adapt to resist the therapy, leading to poorer outcomes and shorter survival.

Read More

Managing the Cardiovascular Complications of Cancer Therapies

Doctors looking at computer screen

Advances in cancer therapies have allowed clinicians to better manage cancer and extend the lives of patients, but many therapies can produce serious cardiovascular side effects, from arrhythmias and hypertension, to cardiomyopathy and even heart failure.

Read More

Reevaluating Treatment Guidelines for Surgically Resected, N1-Positive Stage II NSCLC

doctor looking at imaging in computer

Stage II non-small cell lung cancer (NSCLC) represents less than 10 percent of the approximately 234,000 cases of lung cancer diagnosed each year in the United States. Due to its relatively low incidence, not many papers have been published on stage II NSCLC. Furthermore, few clinicians have extensive experience treating it.

Read More

Researchers Identify Promising New Drug Target for Metastatic Prostate Cancer

Model depicting the mechanism by which selective targeting of PARP-2 attenuates FOXA1/AR signaling and inhibits prostate cancer growth
Model depicting the mechanism by which selective targeting of PARP-2 attenuates FOXA1/AR signaling and inhibits prostate cancer growth.

Although surgery and radiation provide good disease control for localized prostate cancer, developing long-lasting approaches for treating metastatic disease has been challenging because resistance to androgen deprivation therapy (ADT) frequently develops.

Read More

Cancer Moonshot Grant Supports Study of Head and Neck Cancer Immunotherapy Resistance

Image: Multiplex Immunofluorescence of Head and Neck Cancer samples, in collaboration with Scott J. Rodig, MD, PhD.

A collaborative research team at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) has received a grant to study immunotherapy resistance in head and neck cancer. The team is one of a handful to receive a multi-year cancer immunotherapy research grant this year from the National Institutes of Health (NIH) as part of the Cancer Moonshot program.

Read More